The latest announcement is out from Kymera Therapeutics ( (KYMR) ).

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

New Study Shows SIK1 Strengthens Antiviral Immunity to Limit EV-D68–Induced Asthma Exacerbations Asthma is a chronic ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is GSK's depemokimab, a long-acting anti-IL-5 antibody for severe asthma and an ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe asthma that has been billed as a major new product for the drugmaker. In the ...

Adimab's latest partner program to receive approval is GSK's Exdensur (depemokimab), approved in the US for the treatment of severe asthma with an eosinophilic phenotype and in the UK and Japan for ...

Proceeds to advance frevecitinib, an inhaled pan-JAK inhibitor with the potential to treat the broad severe asthma population, through Phase 2 studies ...

Announced new data demonstrating a unique mechanism of action supporting the best-in-class potential of rademikibart – – Recruitment ongoing for Phase 1b study of intravenously-administered ...

The gastroenterology field saw major legal, political and clinical developments over the past year, with implications for patients, physicians and healthcare organizations. Here are five notable ...

After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

EQT Life Sciences invests in U.S.-based Kinaset Therapeutics – a clinical-stage biopharma company developing a novel and differentiated inhaled therapeutic ...

Explore the most influential drug approvals of 2025, highlighting FDA-cleared therapies that impact public health and clinical care.